{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:21:49Z","timestamp":1788517309727,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00HL098692"],"award-info":[{"award-number":["R00HL098692"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL092332"],"award-info":[{"award-number":["T32HL092332"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.coviro.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T19:01:22Z","timestamp":1467486082000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Recent advances in oncolytic adenovirus therapies for cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Amanda","family":"Rosewell Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2016.06.009_bib0225","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coviro.2016.06.009_bib0230","doi-asserted-by":"crossref","first-page":"e947872","DOI":"10.4161\/21624011.2014.947872","article-title":"Healing after death: antitumor immunity induced by oncolytic adenoviral therapy","volume":"3","author":"Jiang","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coviro.2016.06.009_bib0235","doi-asserted-by":"crossref","first-page":"e1117740","DOI":"10.1080\/2162402X.2015.1117740","article-title":"Trial watch-oncolytic viruses and cancer therapy","volume":"3","author":"Pol","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coviro.2016.06.009_bib0240","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd4643","article-title":"Oncolytic viruses get a boost with first FDA-approval recommendation","volume":"14","author":"Dolgin","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2016.06.009_sbref0245","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2016.06.009_bib0250","first-page":"325","article-title":"Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy","volume":"59","author":"Li","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_bib0255","doi-asserted-by":"crossref","first-page":"e0147173","DOI":"10.1371\/journal.pone.0147173","article-title":"Arg-Gly-Asp (RGD)-modified E1A\/E1B double mutant adenovirus enhances antitumor activity in prostate cancer cells in vitro and in mice","volume":"11","author":"Shen","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coviro.2016.06.009_bib0260","first-page":"1271","article-title":"Treatment of ovarian cancer with a tropism modified oncolytic adenovirus","volume":"62","author":"Bauerschmitz","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_bib0265","doi-asserted-by":"crossref","first-page":"12109","DOI":"10.1128\/JVI.01370-06","article-title":"A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells","volume":"80","author":"Tuve","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.06.009_bib0270","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1699-0463.1998.tb00233.x","article-title":"The complement regulatory proteins CD46 and CD59; but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues","volume":"106","author":"Thorsteinsson","year":"1998","journal-title":"APMIS"},{"key":"10.1016\/j.coviro.2016.06.009_bib0275","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2016.06.009_bib0280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/358375a0","article-title":"Transcriptional regulation. A closer look at E2F","volume":"358","author":"Nevins","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.06.009_bib0285","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.coviro.2016.06.009_bib0290","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2010.173","article-title":"Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses","volume":"18","author":"Rojas","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2016.06.009_sbref0295","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.18632\/oncotarget.3544","article-title":"Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic","volume":"6","author":"Sarkar","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.coviro.2016.06.009_bib0300","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3727\/096504013X13657689383139","article-title":"Therapeutic effect of oncolytic adenovirus expressing relaxin in radioresistant oral squamous cell carcinoma","volume":"20","author":"Lee","year":"2013","journal-title":"Oncol Res"},{"key":"10.1016\/j.coviro.2016.06.009_sbref0305","doi-asserted-by":"crossref","first-page":"e0147211","DOI":"10.1371\/journal.pone.0147211","article-title":"Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01","volume":"11","author":"Vera","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coviro.2016.06.009_bib0310","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/0008-5472.CAN-06-4260","article-title":"Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice","volume":"67","author":"Ganesh","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_bib0315","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1158\/1078-0432.CCR-10-1628","article-title":"Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy","volume":"17","author":"Yang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_sbref0320","doi-asserted-by":"crossref","first-page":"e0117254","DOI":"10.1371\/journal.pone.0117254","article-title":"Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer","volume":"18","author":"Lucas","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coviro.2016.06.009_bib0325","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/gt.2012.42","article-title":"Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation","volume":"20","author":"Thaci","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0330","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/ijc.29592","article-title":"Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus","volume":"137","author":"Choi","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coviro.2016.06.009_bib0335","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/cgt.2013.41","article-title":"Combining virotherapy and angiotherapy for the treatment of breast cancer","volume":"20","author":"Bazan-Peregrino","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0340","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.gt.3303038","article-title":"Pharmacokinetic and pharmacodynamics study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors","volume":"15","author":"Li","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0345","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/cbt.6.5.4004","article-title":"A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors","volume":"6","author":"Lin","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0350","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1479-5876-11-257","article-title":"Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells","volume":"11","author":"Li","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.coviro.2016.06.009_bib0355","first-page":"6877","article-title":"Specific oncolytic effect of a new hypoxia-inducible factor dependent replicative adenovirus on von Hippel\u2013Lindau-defective renal cell carcinoma","volume":"63","author":"Cuevas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_bib0360","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1158\/1078-0432.CCR-04-1432","article-title":"Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors","volume":"10","author":"Post","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_bib0365","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.3390\/v7112899","article-title":"Immunostimulatory gene therapy using oncolytic viruses as vehicles","volume":"6","author":"Loskog","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2016.06.009_bib0370","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.it.2015.02.004","article-title":"Macrophages and cancer: from mechanisms to therapeutic implications","volume":"36","author":"Ostuni","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.coviro.2016.06.009_bib0375","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2016.06.009_sbref0380","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coviro.2016.06.009_bib0385","doi-asserted-by":"crossref","first-page":"e1017702","DOI":"10.1080\/2162402X.2015.1017702","article-title":"Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer","volume":"4","author":"Vassilev","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coviro.2016.06.009_sbref0390","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/hum.2014.069","article-title":"Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus","volume":"26","author":"Hirvinen","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0395","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.coviro.2016.06.009_bib0400","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2012.277","article-title":"Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs adeno-associated viral vectors in vivo","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0405","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.177.4.1199","article-title":"Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type 1 (TH1)-specific immune responses and inhibits the development of IL-4-producing TH cells","volume":"177","author":"Manetti","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2016.06.009_bib0410","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/gt.2013.40","article-title":"Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer","volume":"20","author":"Freytag","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0415","doi-asserted-by":"crossref","first-page":"15006","DOI":"10.1038\/mto.2015.6","article-title":"Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer","volume":"2","author":"Fretag","year":"2015","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.coviro.2016.06.009_bib0420","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/hum.2005.16.845","article-title":"Potent antitumor activity of oncolytic adenovirus expressing mda-7\/IL-24 for colorectal cancer","volume":"16","author":"Zhao","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2016.06.009_bib0425","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1007\/s11033-013-2638-8","article-title":"Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice","volume":"40","author":"He","year":"2013","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.coviro.2016.06.009_bib0430","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma\u2014the first phase I\/IIa trial","volume":"16","author":"Malmstrom","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_bib0435","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2016.06.009_bib0440","doi-asserted-by":"crossref","first-page":"14008","DOI":"10.1038\/mto.2014.8","article-title":"Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy","volume":"1","author":"Farzad","year":"2014","journal-title":"Mol Ther Oncolytics"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716300712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T15:55:54Z","timestamp":1536594954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716300712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":44,"alternative-id":["S1879625716300712"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2016.06.009","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in oncolytic adenovirus therapies for cancer","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}